BRPI0919062A2 - anticorpos contra il-25 - Google Patents

anticorpos contra il-25

Info

Publication number
BRPI0919062A2
BRPI0919062A2 BRPI0919062A BRPI0919062A BRPI0919062A2 BR PI0919062 A2 BRPI0919062 A2 BR PI0919062A2 BR PI0919062 A BRPI0919062 A BR PI0919062A BR PI0919062 A BRPI0919062 A BR PI0919062A BR PI0919062 A2 BRPI0919062 A2 BR PI0919062A2
Authority
BR
Brazil
Prior art keywords
antibodies
Prior art date
Application number
BRPI0919062A
Other languages
English (en)
Portuguese (pt)
Inventor
Andrew Neil James Mcenzie
David John Matthews
Jillian Barlow
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council filed Critical Medical Res Council
Publication of BRPI0919062A2 publication Critical patent/BRPI0919062A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0919062A 2008-09-30 2009-09-30 anticorpos contra il-25 BRPI0919062A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10129308P 2008-09-30 2008-09-30
GBGB0817891.5A GB0817891D0 (en) 2008-09-30 2008-09-30 Antibodies against il-25
PCT/IB2009/007302 WO2010038155A2 (en) 2008-09-30 2009-09-30 Antibodies against il-25

Publications (1)

Publication Number Publication Date
BRPI0919062A2 true BRPI0919062A2 (pt) 2015-12-15

Family

ID=40019808

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919062A BRPI0919062A2 (pt) 2008-09-30 2009-09-30 anticorpos contra il-25

Country Status (22)

Country Link
US (1) US8658169B2 (enExample)
EP (1) EP2344538B1 (enExample)
JP (1) JP5719771B2 (enExample)
KR (1) KR101659452B1 (enExample)
CN (1) CN102245638B (enExample)
AU (1) AU2009299465B2 (enExample)
BR (1) BRPI0919062A2 (enExample)
CA (1) CA2739050C (enExample)
CY (1) CY1116313T1 (enExample)
DK (1) DK2344538T3 (enExample)
ES (1) ES2537226T3 (enExample)
GB (1) GB0817891D0 (enExample)
HR (1) HRP20150524T1 (enExample)
ME (1) ME02219B (enExample)
MX (1) MX2011003351A (enExample)
NZ (1) NZ592274A (enExample)
PL (1) PL2344538T3 (enExample)
PT (1) PT2344538E (enExample)
RS (1) RS54028B1 (enExample)
SI (1) SI2344538T1 (enExample)
SM (1) SMT201500144B (enExample)
WO (1) WO2010038155A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0707505D0 (en) 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
PL2552961T3 (pl) * 2010-03-30 2018-04-30 Janssen Biotech, Inc. Humanizowane przeciwciała il-25
JP6284181B2 (ja) * 2012-02-09 2018-02-28 国立研究開発法人理化学研究所 環状ｒｎａ及びタンパク質の製造方法
CN103792375B (zh) * 2014-01-29 2017-07-07 华中科技大学同济医学院附属同济医院 外周血白细胞介素25水平在哮喘分型中的应用及分型方法
US9840557B2 (en) * 2014-09-23 2017-12-12 Regeneron Pharmaceuticals, Inc. Anti-IL-25 antibodies and uses thereof
EP3430046A4 (en) * 2016-03-16 2019-10-23 Abeome Corporation NEUTRALIZING MONOCLONAL ANTIBODIES TO IL-25 AND USES THEREOF
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor
AU2018450414B2 (en) * 2018-11-19 2025-10-16 Beijing Kanova Biopharmaceutical Co., Ltd. Anti-IL-25 antibodies and use thereof
GB202018015D0 (en) * 2020-11-16 2020-12-30 Res & Innovation Uk Composition and methods for the treatment of intestinal cancer
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス， インコーポレイテッド Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート
EP4569000A4 (en) * 2022-08-12 2026-07-15 Lycia Therapeutics Inc Bispecific antibodies and constructions for lysosomal targeting degradation and their methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5071972A (en) 1986-01-31 1991-12-10 Genetics Institute, Inc. DNA sequences encoding novel thrombolytic proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0276846A3 (en) 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6569645B2 (en) 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
NZ542988A (en) 2003-04-23 2008-07-31 Medarex Inc Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies
EP1863520B1 (en) 2005-03-08 2014-12-31 Aptose Biosciences Inc. Use of interleukin 17e for the treatment of cancer
WO2007044450A2 (en) * 2005-10-06 2007-04-19 Baylor Research Institute Compositions and methods for the treatment of cancer
GB0707505D0 (en) * 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
PL2552961T3 (pl) * 2010-03-30 2018-04-30 Janssen Biotech, Inc. Humanizowane przeciwciała il-25
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
PL2344538T3 (pl) 2015-10-30
CY1116313T1 (el) 2017-02-08
CA2739050C (en) 2018-05-29
KR20110086013A (ko) 2011-07-27
CN102245638A (zh) 2011-11-16
WO2010038155A2 (en) 2010-04-08
CA2739050A1 (en) 2010-04-08
ME02219B (me) 2016-02-20
US20110250195A1 (en) 2011-10-13
AU2009299465B2 (en) 2012-07-26
EP2344538A2 (en) 2011-07-20
AU2009299465A1 (en) 2010-04-08
EP2344538B1 (en) 2015-02-25
SMT201500144B (it) 2015-09-07
RS54028B1 (sr) 2015-10-30
NZ592274A (en) 2012-08-31
MX2011003351A (es) 2011-05-25
WO2010038155A3 (en) 2010-05-27
HK1154022A1 (en) 2012-04-13
PT2344538E (pt) 2015-06-19
DK2344538T3 (en) 2015-06-01
ES2537226T3 (es) 2015-06-03
US8658169B2 (en) 2014-02-25
JP2012503979A (ja) 2012-02-16
SI2344538T1 (sl) 2015-07-31
HRP20150524T1 (hr) 2015-08-14
GB0817891D0 (en) 2008-11-05
KR101659452B1 (ko) 2016-09-23
CN102245638B (zh) 2014-10-22
JP5719771B2 (ja) 2015-05-20

Similar Documents

Publication Publication Date Title
EP3064512C0 (en) ANTIBODIES AGAINST CLDN6
BRPI0916973A2 (pt) anticorpos para ccr2
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
HUE037140T2 (hu) Humán GDF8-hoz kötõdõ ellenanyagok
DK3138854T3 (da) Antistoffer mod CD40
IL215696A0 (en) Antibodies specific to cadherin-17
PT2406284T (pt) Anticorpos anti-bcma
BRPI0917148A2 (pt) anticorpos anti-cd5
EP3663193C0 (en) CURVED WING TIP
IL212175B (en) Muc1* antibodies
BRPI1013588A2 (pt) composição
PL2468875T3 (pl) Zintegrowany sposób wytwarzania biopaliw
EP2268582A4 (en) SOLARDESTILLATOREN
EP2339910A4 (en) GLASSHOUSE
EP2414506A4 (en) IMPROVED ENDOGLUCANASES
BRPI0909633A2 (pt) anticorpos anti-tyrp1
SMT201500144B (it) Anticorpi contro IL-25
PL2488554T3 (pl) Przeciwciała przeciw epha3
BRPI0915562A2 (pt) tamis melhorado
BRPI0919559A2 (pt) baterias
BRPI0915442A2 (pt) tamis melhorado
HUE043576T2 (hu) Antitestek notum pektinacetilészterázhoz
FR2928350B1 (fr) Perfectionnements aux emballages en bi-matieres
DK2379722T3 (da) Ekspressionsvektor
BRPI1005318A2 (pt) composição

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25A Requested transfer of rights approved

Owner name: UNITED KINGDOM RESEARCH AND INNOVATION (GB)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]